Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management

Presenter: Aaron T. Gerds

Mutations are a critical piece in understanding how myeloproliferative neoplasms (MPNs) occur, specifically the pathobiology of JAK/STAT activation. Mutations play such an important role, in fact, that they are a key part of the diagnostic classification for these diseases. Furthermore, the mutational landscape of MPNs affects both the prognosis and the biology of disease progression. Current research in the field is focused on understanding how and why these mutations occur, as well as how to attack them to address disease at the time of progression or even before disease progression has occurred.

Disclosures: Dr. Gerds has disclosed receiving consulting fees from AbbVie, Inc., Bristol-Myers Squibb Company, CTI BioPharma Corp., Kartos, Novartis Pharmaceuticals Corporation, PharmaEssentia, and Sierra Oncology.

Correspondence: Aaron T. Gerds, MD, MS, Cleveland Clinic, 9500 Euclid Avenue, CA-60, Cleveland, OH 44195. Email: gerdsa@ccf.org
  • 1.

    Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:17791790.

  • 2.

    Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387397.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:11441148.

  • 4.

    Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:10541061.

  • 5.

    Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:17031708.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369: 23792390.

  • 7.

    Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:18611869.

  • 8.

    Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv 2016;1:2130.

  • 9.

    Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol 2020;189:291302.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 2017;10:156.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 359 359 359
PDF Downloads 196 196 196
EPUB Downloads 0 0 0